earnings
saveNOVARTIS AG earnings
community read0 votes
Anticipated earnings call for NOVARTIS AG ($NVS).
view source ↗Data sources
Found something off?
same company · ±60 days · 6
- phase 1 2 completionzigakibart: Novartis AG — zigakibart (Phase I/II Trial Completion)Apr 30, 2026
- phase 2 initiationasciminib hydrochloride: Novartis AG — asciminib hydrochloride (Phase II Trial Initiation)Apr 25, 2026
- approvalCOSENTYX (SECUKINUMAB) — FDA approvalApr 17, 2026
- approvalCOSENTYX (SECUKINUMAB) — FDA approvalApr 17, 2026
- approvalCOSENTYX (SECUKINUMAB) — FDA approvalApr 17, 2026
- approvalCOSENTYX (SECUKINUMAB) — FDA approvalApr 17, 2026
comments(0)
5-min edit window · permanent after that